Shire (NASDAQ: SHPGY) has secured approval from U.S. regulators for a drug to manage symptoms of Attention Deficit and Hyperactivity Disorder in adults.
Vyvanse has been approved as a maintenance treatment for ADHD. This new approval adds to the indication for Vyvanse as a treatment for ADHD in patients 6 years old and older, according to a statement from Shire.
Vyvanse was launched as a treatment for children with ADHD in the U.S. in 2007, and sales have grown since approval for adults in 2008. The drug is also awaiting regulatory approval in Europe. Shire also launched Intuniv for more difficult-to-treat children in late 2009.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Irish company with U.S. headquarters in Philadelphia, Pennsylvania, has sought to develop other ADHD treatments since losing exclusivity for Adderall to generic rivals in 2009. According to Morningstar analyst Karen Andersen, in 2008, about one-third of Shire’s $3 billion in revenue stemmed from Adderall XR.
